Lilly: Cut costs without 'sweeping layoffs'

Eli Lilly is scuttling its 2008 profit forecast, citing the costs of buying ImClone Systems. The $6.5 billion acquisition will spawn a charge against earnings of $4.05 to $4.50 a share, which will eat up previously expected earnings of $2.44 to $2.49 a share, leaving a loss of up to $2.06.

But without those charges, Lilly predicts healthy EPS of $3.97 to $4.02. And for 2009, the company is looking for $4.30 to $4.55 in EPS. That's because Lilly is counting on big sales growth again next year, powered by growth in Cymbalta, Alimta, Cialis, and Humalog--and, knock on wood, the launch of its long-awaited anticlotting med prasugrel.

Execs are telling analysts and investors this morning that Lilly plans to continue "fundamentally transforming" its business. That means more cost-cutting, more streamlining and more pipeline work. That might sound scary to Lilly employees--except for the fact that the company says it has no plans to make sweeping layoffs.

- see the MarketWatch story
- read the column at the Indianapolis Star

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.